Dyadic prices 6.052mln shares, expects closing on Aug 1, 2025.

• Dyadic International to sell 6,052,000 shares of common stock • Craig-Hallum Capital Group to act as sole managing underwriter • Net proceeds for working capital and general corporate purposes • Product development, sales and marketing to be funded • Closing expected on August 1, 2025, subject to customary conditions.

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company, has announced the pricing of its underwritten public offering of 6,052,000 shares of common stock. The offering is expected to close on August 1, 2025, with Craig-Hallum Capital Group LLC serving as the sole managing underwriter [1].

The company plans to use the net proceeds for working capital and general corporate purposes, including product development, sales, and marketing [1]. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC [1].

This capital raise is significant for Dyadic, which specializes in protein production platforms for life sciences, food, nutrition, and industrial applications. The company's decision to raise capital through equity rather than debt indicates a preference for avoiding interest expenses and maintaining financial flexibility, though at the cost of ownership dilution [1].

The shelf registration approach suggests that management anticipated capital needs and prepared accordingly. With Craig-Hallum as the sole underwriter, Dyadic has opted for a streamlined offering process rather than engaging multiple investment banks, which might impact distribution reach but potentially reduces underwriting costs [1].

The lack of specified pricing details in the release makes it difficult to immediately calculate the dilution impact or total proceeds. For existing shareholders, this represents material dilution of their ownership stakes. The lack of an urgent financial need suggests this may be opportunistic capital raising to strengthen the balance sheet and fund growth initiatives in their protein production platforms [1].

The company's focus on product development, sales, and marketing indicates a strategic direction towards enhancing its competitive edge in the biotechnology sector. The capital raise will support these initiatives, which are crucial for the company's growth and innovation.

References:

[1] https://www.stocktitan.net/news/DYAI/dyadic-international-inc-announces-pricing-of-public-offering-of-6-fkzmbommvo8j.html
[2] https://finance.yahoo.com/news/dyadic-international-inc-announces-proposed-200200313.html